Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/1/26 | Eli Lilly (LLY) | retatrutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/1/26 | Eli Lilly (LLY) | retatrutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/30/26 | Cyclo Therapeutics (CYTH) | Trappsol Cyclo for Niemann-Pick Disease Type C | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/23/26 | Roche (RO) | RG6299 for Immunoglobulin A (IgA) Nephropathy (Berger's Disease) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/22/26 | Roche (RO) | enicepatide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/13/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |